EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Psilocybin as Transformative Fast‐Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms

Makiath Adebo iD, Mathilda Bonnet, Ons Laouej, Celine Defaix, Josephine C McGowan iD, Florence Butlen-Ducuing iD, Denis J David iD, Erwan Poupon, Laurent Tritschler, Alain M Gardier iD

Fundamental & Clinical Pharmacology · 2025

DOI: 10.1111/fcp.70038 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Makiath Adebo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, Inserm CESP/UMR 1018, MOODS Team, Orsay, France. Hauptthemen laut MEDLINE: Psilocybin, Antidepressive Agents, Hallucinogens, Depression. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the 1950s–60s, serotonergic psychedelic drugs were studied as potential adjuvants to psychotherapy to treat addiction and alcoholism. However, starting in the 70s, preclinical and clinical studies on psychedelics stopped for decades because legislation controlled its recreational use, citing their hallucinogenic and psychotomimetic effects, as well as their abuse potential. Amazingly, we are witnessing an impressive return of these drugs due to recent clinical trials suggesting a therapeutic potential of psychedelics, among them psilocybin, for treating patients with depression resistant to conventional antidepressant drugs. Yet, their underlying mechanisms of action remain incompletely elucidated. This review provides an update on seminal clinical trials using psilocybin, as well as preclinical work uncovering the pharmacological properties and experimental pharmacology of psilocybin and its active metabolite psilocin. These drugs are primarily serotonin 5‐HT 2A receptor (5‐HT2AR) agonists. Although there is a consensus that 5‐HT2AR activation mediates its psychedelic effects in human and rodent models of anxiety/depression, its role in psilocin's antidepressant effects remains controversial. This review also provides an overview of neurotransmitter systems, neuroplasticity, and neural circuits activated by psilocin. Further research in developing effective antidepressants for depression is prescient now more than ever, as according to the World Health Organization (WHO), depression will be the main cause of disability in 2030. Understanding the mechanisms through which psilocybin/psilocin would be an effective antidepressant is crucial to ultimately validate its therapeutic potential when combined with SSRIs/SNRIs in mood disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsilocybinAntidepressive AgentsHallucinogensDepressionHumansAnimalsSerotonin 5-HT2 Receptor Agonists

Stichwörter der Autor:innen

antidepressanthumanspsilocinpsilocybinpsychedelicsrodents

Substanzen

PsilocybinAntidepressive AgentsHallucinogensSerotonin 5-HT2 Receptor Agonistspsilocin

Autor:innen und Institutionen

  • Université Paris-Saclay, Inserm CESP/UMR 1018, MOODS Team, Orsay, France.
  • Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts, USA.
  • Institut Gustave Roussy, Psycho-Oncology Unit, Interdisciplinary Department for the Organization of Patient Pathways, Cancer Campus, Grand Paris, France.
  • Université Paris-Saclay, UVSQ, Inserm, CESP/UMR 1018, MOODS Team, Villejuif, France.
  • Université Paris-Saclay, Faculté de Pharmacie, CNRS, BioCIS, Orsay, France.

ORCID-Profile: Makiath Adebo, Josephine C McGowan, Florence Butlen-Ducuing, Denis J David, Alain M Gardier

Zitieren

APA

Adebo, M., Bonnet, M., Laouej, O., Defaix, C., McGowan, J. C., Butlen-Ducuing, F., David, D. J., Poupon, E., Tritschler, L., & Gardier, A. M. (2025). Psilocybin as Transformative Fast‐Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70038

Vancouver

Adebo M, Bonnet M, Laouej O, Defaix C, McGowan JC, Butlen-Ducuing F, et al. Psilocybin as Transformative Fast‐Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70038

BibTeX
@article{Adebo2025,
  author = {Adebo, Makiath and Bonnet, Mathilda and Laouej, Ons and Defaix, Celine and McGowan, Josephine C and Butlen-Ducuing, Florence and David, Denis J and Poupon, Erwan and Tritschler, Laurent and Gardier, Alain M},
  title = {Psilocybin as Transformative Fast‐Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/fcp.70038}
}
Kostenlos starten →